Ophthalmology Deal Benchmarks
Benchmark licensing terms for age-related macular degeneration, glaucoma, dry eye disease, and retinal gene therapy. Ophthalmology deals are driven by high unmet need and premium pricing in retinal diseases. Benchmarks derived from 66 verified transactions.
66
Total Deals
$757M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
22
license
20
acquisition
10
collaboration
9
option
3
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Apellis Pharmaceuticals → Biogen Empaveli / Syfovre | acquisition | $5.6B | $5.6B | Jun 2026 |
MeiraGTx → Johnson & Johnson Bota-vec | acquisition | $130M | $130M | Apr 2026 |
MeiraGTx → Eli Lilly AAV-AIPL1 | license | $75M | — | Mar 2026 |
Ocugen → Kwangdong Pharmaceutical OCU400 | license | $8M | $180M | Sep 2025 |
Adverum Biotechnologies → Eli Lilly Ixoberogene soroparvovec (ixo-vec) acquisition | acquisition | $261M | $261M | Dec 2024 |
EyeBio → Merck retinal_disease | acquisition | $1.3B | $3.0B | Nov 2024 |
Surrozen → Boehringer Ingelheim SZN-413 (Wnt modulator for retina) | co development | $40M | $599M | Jun 2024 |
MeiraGTx → Eli Lilly AAV gene therapy (ophtho collaboration) | co development | $50M | $475M | Jun 2024 |
Ocugen → Bharat Biotech OCU400 | license | $8M | $200M | Feb 2024 |
Aldeyra Therapeutics → AbbVie Reproxalap (dry eye) | option | $100M | $400M | Jan 2024 |
Benchmark Your Ophthalmology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 66 verified ophthalmology transactions.
Ophthalmology Deal Benchmarking FAQ
What drives premium valuations in retinal disease deals?
Retinal disease deals (AMD, diabetic macular edema, geographic atrophy) command premium valuations due to the large addressable market ($15B+ globally), premium pricing ($10K-$20K+ per injection), and long duration of treatment. Gene therapy approaches for inherited retinal diseases add further upside with potential one-time curative pricing.
How are ophthalmology drug delivery deals structured?
Ocular drug delivery platform deals (sustained-release implants, port delivery systems, suprachoroidal injection) are structured as platform licenses with multiple product options. Upfronts range $30M-$150M with per-product milestones and royalties. These deals often include co-development provisions where the platform owner retains manufacturing rights.
What are typical royalty rates for ophthalmology licensing deals?
Ophthalmology royalties typically range 12-22% for retinal products and 8-15% for anterior segment (glaucoma, dry eye). Anti-VEGF biosimilars and next-gen competitors have compressed royalty expectations for AMD, while novel mechanisms (complement inhibitors, gene therapy) still command premium rates above 18%.